Amendment
The purpose of this modification is to add exhibit w acuro letter protocol DARPA 1050.E006, approval issued april 18, 2024, exhibit w acuro letter protocol…
$0
Amendment
The purpose of this modification is to 1 change grants officer from shane lomelin to filza hall, 2 correct exhibit u protocol number from DARPA 1050.E003 to…
$0
Amendment
The purpose of this modification is to 1 extend the period of performance from december 18, 2023 to september 30, 2024 for clins 0001 and 0005 2 change the…
$0
Amendment
The purpose of this modification is to 1 reduce the total amount of the option clin 0002 by $1,411,369 from $3,594,050 to $2,182,681 2 reduce the total…
$0
Amendment
The purpose of this modification is to 1. Change the recipients email address from
$1,682,681
Amendment
The purpose of this modification is to increase the total funded amount by $500,000.00 from $30,755,476.00 to $31,255,476.00
$500,000
Amendment
The purpose of this modification is to: 1) extend the period of performance by 12 months from december 18, 2022 to december 18, 2023 for clins 0001 and 0005, at…
$0
Amendment
This modification corrects the cumulative funding table set forth in P00018 to incorporate 3 lines of accounting that were inadvertently omitted, as shown in…
$0
Amendment
As authorized by cooperative agreement exhibit a, provision 2. Amendment of award and purchase requisition (PR) HR0011259134, this modification: 1) replaces…
$849,000
Amendment
The purpose of this modification is to extend the period of performance by 12 months from december 18, 2021 to december 18, 2022 at no change in cooperative…
$0
Amendment
$1,728,214
Amendment
The purpose of this modification is to: 1) provide incremental funding in the amount of $637,812.00, as authorized by purchase request (PR) HR0011150740, to…
$637,812
Amendment
Covid 19 REA. The purpose of this modification is to revise clin 0003 to add new vumc and bidmc covid workscope to the base periods 3 and 4 increasing clin 0003…
$5,525,769
Amendment
The purpose of this modification is to deobligate $923,130 from clin 0001 subclin 000112, thereby decreasing the funded amount of clin 0001 from $20,861,066…
-$923,130
Amendment
B6 covid 19. The purpose of this modification is to provide incremental funding in the amount of $656,745.00, as authorized by purchase request PR HR0011048291.
$656,745
Amendment
Covid 19. The purpose of this modification is to issue research description document revision 5 to incorporate the changes described below, with a net zero…
$0
Amendment
Covid 19. The purpose of this modification is to create clin 0003 covid-19 research, issue research description document revision 4 to incorporate tasks 3.4 and…
$6,772,325
Amendment
The purpose of this modification is to provide incremental funding in the amount of $325,918 under clin 0001, subclin 000111, acrn ad, as authorized by purchase…
$325,918
Amendment
The purpose of this modification is to correct an error in modification P00007 where the PR numbers in the opening paragraph were associated with the wrong…
$0
Amendment
The purpose of this modification is to provide incremental funding in the amount of $1,000,000 under clin 0001 subclin 000109, acrn AC as authorized by PR…
$1,587,000
Amendment
The purpose of this modification is to provide funding in the amount of 4,963,879 on contract HR0011-18-2-0001 P00005.
$4,963,879
Amendment
$151,214
Amendment
$956,319
Amendment
$3,000,000
Amendment
The purpose of this modification is to provide incremental funding in the amount of 2,000,000 on contract HR0011-18-2-0001 P00001.
$2,000,000
Original award
$2,524,411
Show all 27
Subawards
Subrecipient
Amount
Awarded
Renbio, Inc.RRADD: Rapid Rational Antibody Design and Delivery
HR00111820001 was awarded to Vanderbilt University Medical Center by Defense Advanced Research Projects Agency (Department of Defense) on December 22, 2017.
Vanderbilt University Medical Center UEI GYLUH9UXHDX5
Defense Advanced Research Projects Agency
Department of Defense